BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF

April 28, 2026 10:42 AM EDT DealsR&D BeOne joins the VEGF com­pe­ti­tion, but with a trispe­cif­ic an­ti­body Max Gelman Senior Editor The phar­ma com­pa­ny for­mer­ly known as BeiGene has plucked an ex­per­i­men­tal can­cer drug from a Chi­nese biotech, aim­ing to go broad­er than its com­peti­tors. BeOne … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER